TGFB1 and systemic sclerosis: A combined therapy consisting of plasmapheresis, cyclophosphamide, and allogeneic umbilical-cord-derived MSCs applied to a cohort of 14 SSc patients resulted in decreased skin fibrosis, the size and pain of digital ulcers, and improved lung function, which was accompanied by a decrease in the serum levels of TGF-β and anti-Scl70 autoantibodies in a 12-month follow-up [34,37].